Jignesh Shah, MD
Gastroenterology · Houston, TXNPI 1063550291
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,643 of the $133,610 with a category attached, or 73.1%. Evoke Pharma, Inc. accounts for 76.5% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $73,323, 9.2 times the $7,959 reported in 2019. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 682 payments — averaging $195.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Evoke Pharma, Inc.$102K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$19K
- Ardelyx, Inc.$2K
- Redhill Biopharma Inc.$2K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $5K from 27 others
Across 231 payments — averaging $6974.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Braintree Laboratories, Inc.$677K
- Bausch Health US, LLC$257K
- Pfizer$208K
- Eli Lilly$201K
- AbbVie$127K
- Sanofi US Services Inc.$92K
- plus $48K from 2 others
What the payments were for
- Consulting fees$4,2853%
- Speaking & faculty fees$97,64373%
- Grants$1,0001%
- Travel & lodging$16,74113%
- Food & beverage$13,93410%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Evoke Pharma, Inc. | 102 | $102,199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 190 | $19,435 |
| Ardelyx, Inc. | 33 | $2,097 |
| Redhill Biopharma Inc. | 27 | $2,059 |
| AbbVie | 96 | $1,659 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,490 |
| Braintree Laboratories, Inc. | 9 | $1,146 |
| Madrigal Pharmaceuticals | 32 | $481 |
| QOL Medical, LLC | 3 | $413 |
| Ironwood Pharmaceuticals, Inc | 25 | $398 |
| Johnson & Johnson(2 entities) | 20 | $360 |
| Bristol Myers Squibb | 19 | $332 |
| Pfizer | 15 | $262 |
| Merck | 11 | $229 |
| Gilead | 7 | $156 |
| Inari Medical, Inc. | 1 | $140 |
| Sanofi | 4 | $111 |
| Silk Road Medical, Inc. | 1 | $97 |
| Pulmonx Corporation | 1 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $74 |
| Lilly USA, LLC | 2 | $53 |
| Enterra Medical, Inc. | 1 | $53 |
| Medtronic(2 entities) | 2 | $41 |
| Shionogi Inc | 1 | $33 |
| Conmed Corporation | 1 | $29 |
| Fujifilm Healthcare Americas Corporation | 1 | $27 |
| Boston Scientific | 1 | $26 |
| Ambu Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Axonics, Inc. | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Romark Laboratories, LC | 1 | $14 |
| Cook Medical LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIMOTI$88,380
- TRULANCE$12,716
- XIFAXAN$4,620
- Talicia$1,665
- IBSRELA$1,500
- Sucraid$400
- FLOWTRIEVER CATHETER, S$140
- CT THROMBECTOMY SYSTEM KIT$140
How this compares
$133,610 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 93 | $293,439 |
| IbsrelaTenapanor Hcl | 113 | $250,630 |
| LinzessLinaclotide | 223 | $191,056 |
| TrulancePlecanatide | 157 | $96,720 |
| RezdiffraResmetirom | 20 | $96,546 |
| GimotiMetoclopramide Hcl | 28 | $57,101 |
| Omeprazole | 1,074 | $21,670 |
| Dexlansoprazole DrDexlansoprazole | 79 | $19,779 |
| Mesalamine ErMesalamine | 30 | $19,609 |
| Mesalamine | 67 | $14,577 |
| TaliciaOmeprazole/Amoxicill/Rifabutin | 18 | $14,169 |
| VoqueznaVonoprazan Fumarate | 11 | $12,800 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 84 | $11,454 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 54 | $6,572 |
| Pantoprazole Sodium | 434 | $6,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $19,435 | $401,613334 claims |
| Ardelyx, Inc.Ibsrela | $2,097 | $250,630113 claims |
| AbbVieLinzess | $1,659 | $191,056223 claims |
| Madrigal PharmaceuticalsRezdiffra | $481 | $96,54620 claims |
| Evoke Pharma, Inc.Gimoti | $102,199 | $57,10128 claims |
| Redhill Biopharma Inc.Talicia | $2,059 | $14,16918 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $1,146 | $10,70580 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $1,490 | $3,97612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.